Abbott Laboratories

NYSE:ABT Stock Report

Market Cap: US$194.1b

Abbott Laboratories Valuation

Is ABT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ABT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ABT ($112.42) is trading below our estimate of fair value ($137.61)

Significantly Below Fair Value: ABT is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABT?

Key metric: As ABT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ABT. This is calculated by dividing ABT's market cap by their current earnings.
What is ABT's PE Ratio?
PE Ratio33.9x
EarningsUS$5.74b
Market CapUS$194.14b

Price to Earnings Ratio vs Peers

How does ABT's PE Ratio compare to its peers?

The above table shows the PE ratio for ABT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.5x
ISRG Intuitive Surgical
83.2x11.4%US$187.5b
SYK Stryker
37.9x11.6%US$136.9b
BSX Boston Scientific
72.9x23.3%US$129.7b
MDT Medtronic
23.9x10.2%US$102.6b
ABT Abbott Laboratories
33.9x11.6%US$194.1b

Price-To-Earnings vs Peers: ABT is good value based on its Price-To-Earnings Ratio (33.9x) compared to the peer average (54.5x).

Price to Earnings Ratio vs Industry

How does ABT's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
0.9xn/aUS$7.05m
PAVM PAVmed
0.5x-90.0%US$6.81m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
No more companies available in this PE range
ABT 33.9xIndustry Avg. 34.5xNo. of Companies8PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ABT is good value based on its Price-To-Earnings Ratio (33.9x) compared to the US Medical Equipment industry average (34.5x).

Price to Earnings Ratio vs Fair Ratio

What is ABT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.9x
Fair PE Ratio38.3x

Price-To-Earnings vs Fair Ratio: ABT is good value based on its Price-To-Earnings Ratio (33.9x) compared to the estimated Fair Price-To-Earnings Ratio (38.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$112.42
US$130.00
+15.6%
7.4%US$149.00US$104.00n/a24
Dec ’25US$118.77
US$129.87
+9.3%
7.4%US$149.00US$104.00n/a24
Nov ’25US$118.60
US$129.17
+8.9%
7.6%US$146.00US$104.00n/a24
Oct ’25US$113.56
US$124.29
+9.5%
8.4%US$143.00US$104.00n/a23
Sep ’25US$113.27
US$123.81
+9.3%
8.5%US$143.00US$104.00n/a22
Aug ’25US$110.15
US$124.61
+13.1%
8.0%US$143.00US$104.00n/a22
Jul ’25US$103.20
US$125.15
+21.3%
7.6%US$143.00US$104.00n/a22
Jun ’25US$102.19
US$125.15
+22.5%
7.6%US$143.00US$104.00n/a22
May ’25US$106.29
US$126.33
+18.9%
7.5%US$143.00US$104.00n/a22
Apr ’25US$112.09
US$125.47
+11.9%
7.2%US$141.00US$104.00n/a22
Mar ’25US$118.62
US$124.92
+5.3%
7.2%US$141.00US$104.00n/a22
Feb ’25US$114.49
US$124.54
+8.8%
7.3%US$141.00US$104.00n/a21
Jan ’25US$110.07
US$117.20
+6.5%
7.7%US$133.00US$100.00n/a21
Dec ’24US$104.88
US$116.25
+10.8%
7.9%US$133.00US$100.00US$118.7721
Nov ’24US$95.01
US$116.25
+22.4%
7.9%US$133.00US$100.00US$118.6021
Oct ’24US$96.85
US$123.77
+27.8%
6.5%US$136.00US$104.00US$113.5620
Sep ’24US$102.85
US$123.77
+20.3%
6.5%US$136.00US$104.00US$113.2720
Aug ’24US$110.53
US$124.05
+12.2%
6.3%US$136.00US$104.00US$110.1520
Jul ’24US$109.02
US$122.33
+12.2%
7.3%US$136.00US$103.00US$103.2021
Jun ’24US$102.82
US$121.64
+18.3%
7.7%US$136.00US$103.00US$102.1922
May ’24US$111.11
US$121.97
+9.8%
7.8%US$136.00US$103.00US$106.2921
Apr ’24US$101.26
US$120.10
+18.6%
7.7%US$140.00US$104.00US$112.0922
Mar ’24US$100.83
US$120.61
+19.6%
8.2%US$140.00US$104.00US$118.6222
Feb ’24US$111.82
US$120.61
+7.9%
8.2%US$140.00US$104.00US$114.4922
Jan ’24US$109.79
US$116.48
+6.1%
10.7%US$144.00US$92.00US$110.0724
Dec ’23US$107.93
US$116.15
+7.6%
10.9%US$144.00US$92.00US$104.8823

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 05:45
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abbott Laboratories is covered by 61 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Stephan GasteygerAtlantic Equities LLP
Ishan MajumdarBaptista Research